SCHEMBL2454271

SCHEMBL2454271

Pc1cccc(-c2ccccc2Cl)c1-c1ccccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.44
MAPK14 Q16539 1/20 0.42
DPP4 P27487 1/20 0.42
LMNA P02545 2/20 0.39
TSHR P16473 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
PTPRC P08575 1/20 0.38
POLB P06746 1/20 0.37
KMT2A Q03164 1/20 0.37
PLA2G7 Q13093 1/20 0.37
ALDH1A1 P00352 1/20 0.36
HSD11B1 P28845 1/20 0.36
HTR1A P08908 2/20 0.36
HTR7 P34969 2/20 0.36
IDO1 P14902 1/20 0.35
CYP1A2 P05177 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8852276 0.83 CYP2A6 (0.50) CYP2A6MAPK14DPP4LMNATSHR
SCHEMBL6535680 0.78 ALDH1A1 (0.39) LMNATSHRNPC1RAB9ASMN1; SMN2
SCHEMBL2469822 0.78 CYP2A6 (0.55) CYP2A6MAPK14DPP4LMNATSHR
SCHEMBL29802156 0.77 CYP2A6 (0.67) CYP2A6DPP4LMNATSHRNPC1
SCHEMBL671133 0.77 CYP2A6 (0.67) CYP2A6DPP4LMNATSHRNPC1
SCHEMBL29883244 0.77 CYP2A6 (0.67) CYP2A6DPP4LMNATSHRNPC1
SCHEMBL2232919 0.76 PLA2G7 (0.53) CYP2A6DPP4LMNATSHRNPC1
Ammonia Solution, Strong SCHEMBL735046 0.74 CYP2A6 (0.63) CYP2A6DPP4LMNATSHRNPC1
Hydrogen Sulfide SCHEMBL8574751 0.74 CYP2A6 (0.63) CYP2A6DPP4LMNATSHRNPC1
Hydrogen Sulfide SCHEMBL9195473 0.74 CYP2A6 (0.63) CYP2A6DPP4LMNATSHRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642803-B2 Preparation of ethylenically unsaturated carboxylic salts by carboxylation of alkenes BASF SE (DE) 2014-02-04 US disclosed
US-20110218359-A1 PREPARATION OF ETHYLENICALLY UNSATURATED CARBOXYLIC SALTS BY CARBOXYLATION OF ALKENES BASF SE (DE) 2011-09-08 US disclosed
US-5792884-A HEATING PHOSPHINE DIHALIDE IN PRESENCE OF POWDERED SILICON YIELDS TERTIARY PHOSPHINE AND LIQUID SILICON TETRAHALIDES WHICH CAN BE REMOVE BY DISTILLATION AND USED AS INTERMEDIATES FOR PURE SILICON AND ORGANOSILICON COMPOUNDS BASF AKTIENGESELLSCHAFT (DE) 1998-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218359-A1 PREPARATION OF ETHYLENICALLY UNSATURATED CARBOXYLIC SALTS BY CARBOXYLATION OF ALKENES ARCN1, COPE, ELL CYP2A6 1477/4885MAPK14 4014/4885DPP4 4704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.